Lazard Asset Management
PLX icon

Lazard Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Lazard Asset Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Buy
165,561
+78,944
+91% +$167K ﹤0.01% 1491
2026
Q1 		$188K Buy
86,617
+15,224
+21% +$37.8K ﹤0.01% 1640
2025
Q4 		$129K Buy
+71,393
New +$146K ﹤0.01% 1719
2025
Q2 		– Sell
-797
Closed -$2K – 2479
2025
Q1 		$2K Sell
797
-458
-36% -$1.09K ﹤0.01% 2209
2024
Q4 		$2K Buy
+1,255
New +$1.77K ﹤0.01% 2188

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lazard Asset Management's PLX Position: Q2 2026 in Review

Lazard Asset Management increased its Protalix BioTherapeutics (PLX) stake by 91% in Q2 2026, buying an estimated $167K and bringing the position to 165,561 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #1491.

Lazard Asset Management first reported a position in PLX in Q4 2024 and has held it in 5 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Lazard Asset Management held 165,561 shares of Protalix BioTherapeutics worth $386K as of Q2 2026.
  • Lazard Asset Management bought 78,944 Protalix BioTherapeutics shares in Q2 2026, an estimated $167K.
  • Protalix BioTherapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1491 holding.
  • Lazard Asset Management first reported a position in Protalix BioTherapeutics in Q4 2024 and has held it in 5 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.